Adverum Biotechnologies Inc (ADVM) Stock Price, Quote & News

Company Profile

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a f...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 656 9323

Fax: 650 649 1995

Website: adverum.com

Address:

100 Cardinal Way, Redwood City, United States

MGeronimo Jul. 10 at 10:30 PM

$ADVM IN AT 2.77 on good management and potential of product pipeline long term lottery play

0 · Reply

alexx013 Jul. 10 at 3:17 PM

$ADVM started climbing

1 · Reply

dthekang Jul. 2 at 2:54 PM

$ADVM nobody really gives shit abt this stock lol get out of the sinking ship if you are on it!

1 · Reply

clockwatch2 Jul. 1 at 6:49 PM

$ADVM we got kicked off the russell 3000

2 · Reply

clockwatch2 Jun. 30 at 1:53 PM

$ADVM

0 · Reply

Capitulation_0 Jun. 26 at 6:30 PM

$ADVM Mizhuo outperform 12 RBC 4 Chardan capital 33 HCW 30 No one fucking knows. oh Management bought in the 5,4,3s... So they don't fucking know.

0 · Reply

anachartanalyst Jun. 26 at 5:02 PM

$ADVM https://anachart.com/wp-content/uploads/ana_temp/1750957330_soc-img.jpg

0 · Reply

JarvisFlow Jun. 26 at 3:00 PM

Mizuho has updated their rating for Adverum Biotechnologies ( $ADVM ) to Outperform with a price target of 12.

0 · Reply

dthekang Jun. 25 at 5:53 PM

$ADVM POS

0 · Reply

Kosmokrat Jun. 24 at 11:46 AM

$ADVM Currently Adverum runs the OPTIC, the LUNA, and the ARTEMIS trial to gather data an safety and efficacy of Ixo-Vec. But when do they plan to file for FDA approval? How much data will they need? Do you have any estimate on the timing of the FDA filing?

1 · Reply

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2025, 4:05 PM EDT - 2 months ago

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

Apr 30, 2025, 10:00 AM EDT - 2 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 29, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Shareholders to Inquire about Securities Investigation

Apr 28, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Shareholders to Connect

Apr 25, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation

Apr 24, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Adverum Biotechnologies, Inc. (ADVM) and Encourages Investors to Learn More About the Investigation

Apr 23, 2025, 10:00 AM EDT - 2 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 22, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Connect

Apr 20, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation

Apr 18, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out

Apr 17, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out

Apr 16, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect

Apr 15, 2025, 12:00 PM EDT - 3 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 15, 2025, 9:09 AM EDT - 3 months ago

ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm

Apr 4, 2025, 4:05 PM EDT - 3 months ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 4:01 PM EDT - 3 months ago

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 3, 2025, 4:01 PM EST - 4 months ago

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Feb 25, 2025, 7:00 AM EST - 4 months ago

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Feb 5, 2025, 4:05 PM EST - 5 months ago

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 20, 2024, 4:05 PM EST - 8 months ago

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 18, 2024, 1:37 PM EST - 8 months ago

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Nov 15, 2024, 4:05 PM EST - 8 months ago

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Nov 4, 2024, 4:39 PM EST - 8 months ago

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Oct 16, 2024, 8:00 AM EDT - 9 months ago

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Sep 4, 2024, 4:05 PM EDT - 11 months ago

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jul 17, 2024, 3:35 PM EDT - 1 year ago

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Jul 17, 2024, 2:45 AM EDT - 1 year ago

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

May 9, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

May 3, 2024, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Feb 28, 2024, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 8, 2024, 7:00 AM EST - 1 year ago

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Feb 5, 2024, 7:45 AM EST - 1 year ago

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

Feb 1, 2024, 5:30 PM EST - 1 year ago

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Jan 29, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Dec 7, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

Nov 28, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

Nov 9, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Nov 6, 2023, 8:00 AM EST - 1 year ago

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D.

Nov 4, 2023, 5:54 PM EDT - 1 year ago

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Sep 26, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

MGeronimo Jul. 10 at 10:30 PM

$ADVM IN AT 2.77 on good management and potential of product pipeline long term lottery play

0 · Reply

alexx013 Jul. 10 at 3:17 PM

$ADVM started climbing

1 · Reply

dthekang Jul. 2 at 2:54 PM

$ADVM nobody really gives shit abt this stock lol get out of the sinking ship if you are on it!

1 · Reply

clockwatch2 Jul. 1 at 6:49 PM

$ADVM we got kicked off the russell 3000

2 · Reply

clockwatch2 Jun. 30 at 1:53 PM

$ADVM

0 · Reply

Capitulation_0 Jun. 26 at 6:30 PM

$ADVM Mizhuo outperform 12 RBC 4 Chardan capital 33 HCW 30 No one fucking knows. oh Management bought in the 5,4,3s... So they don't fucking know.

0 · Reply

anachartanalyst Jun. 26 at 5:02 PM

$ADVM https://anachart.com/wp-content/uploads/ana_temp/1750957330_soc-img.jpg

0 · Reply

JarvisFlow Jun. 26 at 3:00 PM

Mizuho has updated their rating for Adverum Biotechnologies ( $ADVM ) to Outperform with a price target of 12.

0 · Reply

dthekang Jun. 25 at 5:53 PM

$ADVM POS

0 · Reply

Kosmokrat Jun. 24 at 11:46 AM

1 · Reply

alexx013 Jun. 18 at 6:58 PM

$ADVM bought some more @ 2.23

0 · Reply

SecondChances Jun. 17 at 6:47 PM

$ADVM anyone knows what happened in today’s shareholders meeting?

2 · Reply

clockwatch2 Jun. 13 at 3:25 PM

$ADVM someday

1 · Reply

socke2003 Jun. 12 at 1:37 PM

$ADVM why we goes Down? Bad News???

1 · Reply

alexx013 Jun. 10 at 2:33 PM

$ADVM 3 busted, next 4

0 · Reply

flinder1f7 Jun. 10 at 2:31 PM

$ADVM any chart experts here, I would like to take some profit and reenter again

0 · Reply

alexx013 Jun. 9 at 1:38 PM

$ADVM lets bust 3 today

0 · Reply

Kosmokrat Jun. 9 at 12:40 PM

Any idea on how $ADVM will raise cash to sustain operations throughout 2025 and beyond? Partner deal including upfront / milestone payments? Or a BO? Maybe strike a deal with Royalty Pharma, to bridge the gap of a successful phase 3 study and the first sales revenue? Or a diluting capital injection? What's your guess?

1 · Reply

alexx013 Jun. 6 at 3:59 PM

$ADVM this will at least double by eoy

0 · Reply

builderup Jun. 6 at 3:13 PM

$ADVM Patience is key. 😊. Been waiting on this move. Let’s go

0 · Reply

builderup Jun. 6 at 2:52 PM

Whatever I buy I’m willing to hold for 90 days. Call it swing trading or position or whatever. Looking back at this post I was a little cautious with my predictions. Nailed it. Not saying I hit it everytime but not bad. $CTMX $OMI $RLAY $ADVM

0 · Reply

dthekang Jun. 5 at 1:58 PM

$ADVM fallin fast and steady LOl

0 · Reply

Market Cap	53.06M
Revenue (ttm)	1.00M
Net Income (ttm)	-130.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,093.00%
Debt to Equity Ratio	0.00

Volume	65,700
Avg Vol	353,724
Day's Range	N/A - N/A
Shares Out	20.89M
Stochastic %K	67%
Beta	0.70
Analysts	Strong Sell
Price Target	$19.75